189 related articles for article (PubMed ID: 23157677)
1. The non-canonical IκB kinases IKKε and TBK1 as potential targets for the development of novel therapeutic drugs.
Niederberger E; Möser CV; Kynast KL; Geisslinger G
Curr Mol Med; 2013 Aug; 13(7):1089-97. PubMed ID: 23157677
[TBL] [Abstract][Full Text] [Related]
2. IκB kinase ε (IKKε): a therapeutic target in inflammation and cancer.
Verhelst K; Verstrepen L; Carpentier I; Beyaert R
Biochem Pharmacol; 2013 Apr; 85(7):873-80. PubMed ID: 23333767
[TBL] [Abstract][Full Text] [Related]
3. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation.
Clark K; Plater L; Peggie M; Cohen P
J Biol Chem; 2009 May; 284(21):14136-46. PubMed ID: 19307177
[TBL] [Abstract][Full Text] [Related]
4. Identification of TBK1 and IKKε, the non-canonical IκB kinases, as crucial pro-survival factors in HTLV-1-transformed T lymphocytes.
Zhang H; Chen L; Cai SH; Cheng H
Leuk Res; 2016 Jul; 46():37-44. PubMed ID: 27123832
[TBL] [Abstract][Full Text] [Related]
5. The TRAF-associated protein TANK facilitates cross-talk within the IkappaB kinase family during Toll-like receptor signaling.
Clark K; Takeuchi O; Akira S; Cohen P
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17093-8. PubMed ID: 21949249
[TBL] [Abstract][Full Text] [Related]
6. SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus-triggered IRF-3 activation pathways.
Huang J; Liu T; Xu LG; Chen D; Zhai Z; Shu HB
EMBO J; 2005 Dec; 24(23):4018-28. PubMed ID: 16281057
[TBL] [Abstract][Full Text] [Related]
7. TBK1 and IKKε Act Redundantly to Mediate STING-Induced NF-κB Responses in Myeloid Cells.
Balka KR; Louis C; Saunders TL; Smith AM; Calleja DJ; D'Silva DB; Moghaddas F; Tailler M; Lawlor KE; Zhan Y; Burns CJ; Wicks IP; Miner JJ; Kile BT; Masters SL; De Nardo D
Cell Rep; 2020 Apr; 31(1):107492. PubMed ID: 32268090
[TBL] [Abstract][Full Text] [Related]
8. Functionally distinct effects of the C-terminal regions of IKKε and TBK1 on type I IFN production.
Nakatsu Y; Matsuoka M; Chang TH; Otsuki N; Noda M; Kimura H; Sakai K; Kato H; Takeda M; Kubota T
PLoS One; 2014; 9(4):e94999. PubMed ID: 24722368
[TBL] [Abstract][Full Text] [Related]
9. Regulation and function of IKK and IKK-related kinases.
Häcker H; Karin M
Sci STKE; 2006 Oct; 2006(357):re13. PubMed ID: 17047224
[TBL] [Abstract][Full Text] [Related]
10. Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity.
tenOever BR; Sharma S; Zou W; Sun Q; Grandvaux N; Julkunen I; Hemmi H; Yamamoto M; Akira S; Yeh WC; Lin R; Hiscott J
J Virol; 2004 Oct; 78(19):10636-49. PubMed ID: 15367631
[TBL] [Abstract][Full Text] [Related]
11. Encephalomyocarditis virus 3C protease attenuates type I interferon production through disrupting the TANK-TBK1-IKKε-IRF3 complex.
Huang L; Xiong T; Yu H; Zhang Q; Zhang K; Li C; Hu L; Zhang Y; Zhang L; Liu Q; Wang S; He X; Bu Z; Cai X; Cui S; Li J; Weng C
Biochem J; 2017 Jun; 474(12):2051-2065. PubMed ID: 28487378
[TBL] [Abstract][Full Text] [Related]
12. DDX3 directly facilitates IKKα activation and regulates downstream signalling pathways.
Fullam A; Gu L; Höhn Y; Schröder M
Biochem J; 2018 Nov; 475(22):3595-3607. PubMed ID: 30341167
[TBL] [Abstract][Full Text] [Related]
13. Nuclear accumulation of cRel following C-terminal phosphorylation by TBK1/IKK epsilon.
Harris J; Olière S; Sharma S; Sun Q; Lin R; Hiscott J; Grandvaux N
J Immunol; 2006 Aug; 177(4):2527-35. PubMed ID: 16888014
[TBL] [Abstract][Full Text] [Related]
14. TANK-binding kinase 1 (TBK1) modulates inflammatory hyperalgesia by regulating MAP kinases and NF-κB dependent genes.
Möser CV; Stephan H; Altenrath K; Kynast KL; Russe OQ; Olbrich K; Geisslinger G; Niederberger E
J Neuroinflammation; 2015 May; 12():100. PubMed ID: 25997745
[TBL] [Abstract][Full Text] [Related]
15. IKKε and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKKε/TBK1 inhibitor to repress NF-κB and IL-10 signalling.
Carr M; Mamand S; Chapman KL; Perrior T; Wagner SD
J Cell Mol Med; 2020 Oct; 24(19):11573-11582. PubMed ID: 32858764
[TBL] [Abstract][Full Text] [Related]
16. Polyubiquitin binding to optineurin is required for optimal activation of TANK-binding kinase 1 and production of interferon β.
Gleason CE; Ordureau A; Gourlay R; Arthur JSC; Cohen P
J Biol Chem; 2011 Oct; 286(41):35663-35674. PubMed ID: 21862579
[TBL] [Abstract][Full Text] [Related]
17. Dual TBK1/IKKε inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro.
Zhou Z; Qi J; Lim CW; Kim JW; Kim B
Toxicology; 2020 Nov; 444():152579. PubMed ID: 32905826
[TBL] [Abstract][Full Text] [Related]
18. Non-canonical IKKs, IKKϵ and TBK1, as novel therapeutic targets in the treatment of non-small cell lung cancer.
Kim JY; Beg AA; Haura EB
Expert Opin Ther Targets; 2013 Oct; 17(10):1109-12. PubMed ID: 23984985
[TBL] [Abstract][Full Text] [Related]
19. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.
Fitzgerald KA; McWhirter SM; Faia KL; Rowe DC; Latz E; Golenbock DT; Coyle AJ; Liao SM; Maniatis T
Nat Immunol; 2003 May; 4(5):491-6. PubMed ID: 12692549
[TBL] [Abstract][Full Text] [Related]
20. The Specific IKKε/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-κB and MAP Kinase Pathways.
Möller M; Wasel J; Schmetzer J; Weiß U; Meissner M; Schiffmann S; Weigert A; Möser CV; Niederberger E
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
